Vertex insider plans sale of 4,500 shares

Vertex Pharmaceuticals insider Ourania Tatsis has filed a notice to sell common stock under Rule 144.

Rhea-AI Filing Summary

Vertex Pharmaceuticals insider Ourania Tatsis has filed a notice to sell common stock under Rule 144. The filing covers 4,500 shares of Vertex common stock to be sold through Fidelity Brokerage Services on NASDAQ, with an aggregate market value of $2,137,455.00, against 253,718,831 shares outstanding.

The shares to be sold were acquired mainly through restricted stock vesting on several dates in 2021 and 2024, plus a small purchase through the employee stock purchase plan in May 2024. The notice also reports that Tatsis sold 4,500 Vertex common shares on 12/03/2025 for gross proceeds of $2,024,955.40. By signing, the seller represents not knowing any undisclosed material adverse information about the company’s operations.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Who is the insider selling Vertex (VRTX) shares in this Form 144?

The notice identifies Ourania Tatsis as the person for whose account Vertex common stock is to be sold.

How many Vertex (VRTX) shares are planned to be sold and on which exchange?

The filing covers 4,500 shares of Vertex common stock to be sold on the NASDAQ, with an aggregate market value of $2,137,455.00.

When is the approximate sale date for these Vertex (VRTX) shares?

The approximate date of sale listed in the notice is 01/07/2026.

How were the Vertex (VRTX) shares being sold under this Form 144 originally acquired?

The shares were acquired mainly through restricted stock vesting on several dates in 2021 and 2024, plus an ESPP purchase on 05/14/2024 paid in cash.

What prior Vertex (VRTX) share sales by this insider are disclosed in the past 3 months?

The notice reports that Ourania Tatsis sold 4,500 Vertex common shares on 12/03/2025 for $2,024,955.40 in gross proceeds.

What does the Form 144 representation say about undisclosed information at Vertex (VRTX)?

By signing, the seller represents that they do not know any material adverse information about the issuer’s current or prospective operations that has not been publicly disclosed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/07/2026 - 10:31 AM EST Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001789815
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	VERTEX PHARMACEUTICALS INC / MA
SEC File Number	000-19319
Address of Issuer	50 NORTHERN AVENUE BOSTON MASSACHUSETTS 02210
Phone	6173416393
Name of Person for Whose Account the Securities are To Be Sold	Tatsis Ourania
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	4500	2137455.00	253718831	01/07/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/10/2021	Restricted Stock Vesting	Issuer			460	02/10/2021	Compensation
Common	02/10/2024	Restricted Stock Vesting	Issuer			1	02/10/2024	Compensation
Common	02/17/2024	Restricted Stock Vesting	Issuer			2162	02/17/2024	Compensation
Common	02/20/2024	Restricted Stock Vesting	Issuer			1808	02/20/2024	Compensation
Common	05/14/2024	ESPP Purchase	Issuer			69	05/14/2024	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Ourania Tatsis 50 Northern Avenue Boston MA 02210	Common	12/03/2025	4500	2024955.40

144: Remarks and Signature

Remarks
Date of Notice	01/07/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	08/21/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Gary Redman, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Ourania Tatsis
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)